Evidence map›Paper›PMID 31040376›Full record

ArticleScientific reports2019

Disaccharides obtained from carrageenans as potential antitumor agents.

Gustavo H Calvo, Vanina A Cosenza, Daniel A Sáenz, Diego A Navarro, Carlos A Stortz, Mariela A Céspedes, Leandro A Mamone, Adriana G Casas, Gabriela M Di Venosa

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 90 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Expanding the application range of theMarine life science & technology · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Carrageenans and Their Oligosaccharides from Red SeaweedsInternational journal of molecular sciences · 2023
    Article
  13. Article
  14. Article
  15. Review
  16. Carrageenan FromFrontiers in plant science · 2022
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Gustavo H CalvoCentro de Investigaciones sobre Porfirinas y Porfirias (CIPYP), Hospital de Clínicas José de San Martin, Universidad de Buenos Aires and CONICET, Av. Córdoba 2351, 1er subsuelo, Ciudad Autónoma de Buenos Aires, 1120AAF, Argentina.
Vanina A CosenzaCIHIDECAR- CONICET - Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pab. 2, Ciudad de Buenos Aires, 1428, Argentina.
Daniel A SáenzCentro de Investigaciones sobre Porfirinas y Porfirias (CIPYP), Hospital de Clínicas José de San Martin, Universidad de Buenos Aires and CONICET, Av. Córdoba 2351, 1er subsuelo, Ciudad Autónoma de Buenos Aires, 1120AAF, Argentina.
Diego A NavarroCIHIDECAR- CONICET - Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pab. 2, Ciudad de Buenos Aires, 1428, Argentina.
Carlos A StortzCIHIDECAR- CONICET - Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Ciudad Universitaria, Pab. 2, Ciudad de Buenos Aires, 1428, Argentina.
Mariela A CéspedesCentro de Investigaciones sobre Porfirinas y Porfirias (CIPYP), Hospital de Clínicas José de San Martin, Universidad de Buenos Aires and CONICET, Av. Córdoba 2351, 1er subsuelo, Ciudad Autónoma de Buenos Aires, 1120AAF, Argentina.
Leandro A MamoneCentro de Investigaciones sobre Porfirinas y Porfirias (CIPYP), Hospital de Clínicas José de San Martin, Universidad de Buenos Aires and CONICET, Av. Córdoba 2351, 1er subsuelo, Ciudad Autónoma de Buenos Aires, 1120AAF, Argentina.
Adriana G CasasCentro de Investigaciones sobre Porfirinas y Porfirias (CIPYP), Hospital de Clínicas José de San Martin, Universidad de Buenos Aires and CONICET, Av. Córdoba 2351, 1er subsuelo, Ciudad Autónoma de Buenos Aires, 1120AAF, Argentina.
Gabriela M Di VenosaCentro de Investigaciones sobre Porfirinas y Porfirias (CIPYP), Hospital de Clínicas José de San Martin, Universidad de Buenos Aires and CONICET, Av. Córdoba 2351, 1er subsuelo, Ciudad Autónoma de Buenos Aires, 1120AAF, Argentina. gabrieladivenosa@yahoo.com.ar.
Hospital de Clínicas "José de San Martín" · ARUniversity of Buenos Aires · ARConsejo Nacional de Investigaciones Científicas y Técnicas · ARFundación Ciencias Exactas y Naturales · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carrageenans are sulfated galactans found in certain red seaweeds with proven biological activities. In this work, we have prepared purified native and degraded κ-, ι-; and λ-carrageenans, including the disaccharides (carrabioses) and disaccharide-alditols (carrabiitols) from seaweed extracts as potential antitumor compounds and identified the active principle of the cytotoxic and potential antitumor properties of these compounds. Both κ and ι-carrageenan, as well as carrageenan oligosaccharides showed cytotoxic effect over LM2 tumor cells. Characterized disaccharides (carrabioses) and the reduced product carrabiitols, were also tested. Only carrabioses were cytotoxic, and among them, κ-carrabiose was the most effective, showing high cytotoxic properties, killing the cells through an apoptotic pathway. In addition, the cells surviving treatment with κ-carrabiose, showed a decreased metastatic ability in vitro, together with a decreased cell-cell and cell-matrix interactions, thus suggesting possible antitumor potential. Overall, our results indicate that most cytotoxic compounds derived from carrageenans have lower molecular weights and sulfate content. Potential applications of the results emerging from the present work include the use of disaccharide units such as carrabioses coupled to antineoplasics in order to improve its cytotoxicity and antimetastatic properties, and the use of ι-carrageenan as adjuvant or carrier in anticancer treatments.

Indexed as

AnimalsAntineoplastic AgentsBiological ProductsCarrageenanCell CycleCell Line, TumorCell MovementCell SurvivalDisaccharidesMiceMolecular StructureAntineoplastic AgentsBiological ProductsCarrageenanDisaccharides

Identifiers

PMID31040376
PMCPMC6491800
OpenAlexW2943022158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.